Qi Ling

Qi Ling

Auto-generated profile, based on publicly available information

Qi Ling

State Key Laboratory of Soil and Water Conservation and Desertification Control, College of Soil and Water Conservation Science and Engineering Northwest A&F University Yangling Shaanxi China

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2023 in Journal of Hydrology
Verified
Journal Article
Closed access
BYBo Yang
Bo Yang
JJJuying Jiao
Juying Jiao
XMXiaowu Ma
Xiaowu Ma
WZWenting Zhao
Wenting Zhao
QLQi Ling
Qi Ling
Hao ChenHao Chen
Hao Chen

28 May 2008 in Schizophrenia Research
Verified
Journal Article
Closed access
PDF file
SSShillong Sun
Shillong Sun
FWFan Wang
Fan Wang
LCLian Luan Cao
Lian Luan Cao
LQLing Yan Qi
Ling Yan Qi
MXMeihong Xiu
Meihong Xiu
Xiangyang ZhangXiangyang Zhang
Xiangyang Zhang

20 May 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BZBo Zhang
Bo Zhang
LQLing Qi
Ling Qi
XWXi Wang
Xi Wang
JJJun Jiang
Jun Jiang
XZXin Zhang
Xin Zhang
JHJing Huang
Jing Huang
4033 Background: Both anti-PD-1 antibodies and molecular antiangiogenic agents have shown promising anti-tumor activities in patients with advanced esophageal cancer. We conducted this single-center phase 2 study to evaluate the efficacy and safety of camrelizumab (anti-PD-1 antibody) plus apatinib (VEGFR2-TKI) in combination with liposomal paclitaxel and nedaplatin in the first-line treatment of patients with esophageal squamous cell carcinoma (ESCC). Methods: Patients with unresectable locally advanced or metastatic ESCC received camrelizumab 200mg d1, liposomal paclitaxel 150mg/m2 d1, nedaplatin 50mg/m2 d1 and apatinib 250mg d1-14. Treatments were repeated every 14 days for up to 6-9 cycles, followed by maintenance therapy with camrelizumab, apatinib, or both. The primary end point was progression-free survival (PFS) in the intention-to-treat population. Secondary end points included objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety. PD-L1 positivity, defined as a combined positive score (CPS) ≥1, was evaluated by immunohistochemistry (IHC). Results: Between Aug 6th 2018 and Feb 6th 2019, a total of 29 patients were enrolled. The median age was 62 years (43-70). Most patients were male (22/29, 75.9%) with metastatic disease (25/29, 86.2%). Response evaluation by independent central review was available in 26 patients, with 19 achieving a best response of PR, 6 with SD, and 1 with PD. The ORR and DCR were 73.1% (19/26) and 96.2% (25/26), respectively. Data for PFS and OS were not matured. The most common grade 3/4 adverse events were leucopenia (21/29, 72.4%) and neutropenia (15/29, 51.7%). Two cases of treatment-related SAEs occurred, both led to hospitalization: one patient developed grade 3 febrile neutropenia, grade 4 leucopenia and grade 3 anorexia; another patient developed grade 4 toxic epidermal necrolysis. Conclusions: Camrelizumab plus apatinib in combination with liposomal paclitaxel and nedaplatin could be a new treatment option for patients with unresectable locally advanced or metastatic ESCC. Clinical trial information: NCT03603756.

25 August 2026 in Earth Surface Processes and Landforms
Verified
Journal Article
Closed access
PDF file
BYBo Yang
Bo Yang
JJJuying Jiao
Juying Jiao
XMXiaowu Ma
Xiaowu Ma
WZWenting Zhao
Wenting Zhao
QLQi Ling
Qi Ling
JLJianJun Li
JianJun Li

28 October 2026 in Geomorphology
Verified
Journal Article
Closed access
QLQi Ling
Qi Ling
JJJuying Jiao
Juying Jiao
BYBo Yang
Bo Yang
XMXiaowu Ma
Xiaowu Ma
WZWenting Zhao
Wenting Zhao
JJJinshi Jian
Jinshi Jian